Navigation Links
Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
Date:12/10/2012

WESTON, Mass. and CARLSBAD, Calif., Dec. 10, 2012 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.  Biogen Idec and Isis are also developing antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations. 

"Our latest collaboration with Isis to discover and develop novel targets for the treatment of neurological disorders is a perfect fit within our early-stage research strategy," said Richard Brudnick, vice president and co-head of business development at Biogen Idec. "This will be our third collaboration with Isis, which is reflective of our respect for them as a partner and as a leader in antisense technology. By combining Isis' knowledge with Biogen Idec's expertise as a leader in neurology, we believe this latest discovery collaboration holds great potential for finding novel approaches to treating neurologic diseases."

Under the terms of the agreement, Isis will receive an upfront payment of $30 million and is responsible for the discovery of a lead antisense drug for each of the three undisclosed targets. Isis is eligible to receive substantial development milestone payments to support research and development of each program prior to the exercise by Biogen Idec of its option to license each program.  Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials. Isis could receive up to another $200 million in a license fee and regulatory milestone payments per program. In addition
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 14, 2012 The Merz Pharma Group today announced ... of the US holding company, Merz Inc., effective March ... overall responsibility for the Medical Dermatology global business unit ... North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. ...
... Smith, among the nation,s largest pharmaceutical wholesalers, today ... chief financial officer (CFO). Mr. Williams, who served recently ... chairman and chief executive Dale Smith, and joins ... (Photo:  http://photos.prnewswire.com/prnh/20120314/NY69737 ) ...
Cached Medicine Technology:The Merz Pharma Group Appoints William D. Humphries As New North American Chief Executive Officer 2H. D. Smith Appoints Bill Williams Chief Financial Officer 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in Germany ... from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph partner ... Geospatial’s ERDAS APOLLO for cataloging, managing, and ... clouds and documents. This effort will enable the State ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... treats mountaineers caught in avalanches and slipped in crevasses. She ... now offered to cope with a new emergency// - the ... for Louisiana on Thursday, one of the worst-affected American coastal ... killed thousands. ,She will set up an emergency ...
... cells grow and spread rapidly. Recent research on the ... is associated //with loss of regulatory protein., , ... estrogen in their laboratory showed a dramatic reduction in ... known as N-CoR . They also found that the ...
... the womb of pregnant women can be damaged by chemicals ... found that these chemicals reach the baby from// the mother ... newborn babies and 42 new mothers. The samples were tested ... positive for 35 samples tested. Some of the umbilical cord ...
... in household dust is sufficient enough to produce ... asthma-related symptoms such as wheezing.// A ... and the prevalence of diagnosed asthma, asthma symptoms, ... strongest for bedroom floor and bedding dust. Households ...
... latest issue of JAMA, which deals with medical education ... US medical schools receive on an average one gift ... per week and often feel that sponsored educational events ... with progressively fewer boundaries between medicine and the pharmaceutical ...
... Japanese Encephalitis epidemic continues to cause deaths in the ... tight-lipped about the toll in a Japanese encephalitis epidemic; ... disease had claimed 591 lives.// ,As many as ... died in Gorakhpur, the town with the best medical ...
Cached Medicine News:Health News:Toxic chemicals found in domestic products poisoning newborn babies 2Health News:Is your house safe enough to protect against asthma attacks? 2Health News:Pharma Companies May Influence The Decisions Of Medical Students 2
Inquire...
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
Medicine Products: